Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Piperacillin/tazobactam Clear all
Completed Phase 3 Interventional

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

NCT03687255
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
cefepime/AAI101 combination, Piperacillin/tazobactam
Drug
Lead sponsor
Allecra
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anaheim, California • Buena Park, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Antibiotic Safety (SCAMP)

NCT01994993
View directory record Official record
Conditions
Complicated Intra Abdominal Infections
Interventions
ampicillin and metronidazole and gentamicin, ampicillin and gentamicin and clindamycin, gentamicin and Piperacillin- tazobactam, standard of care antibiotics and metronidazole, metronidazole, clindamycin, or piperacillin-tazobactam
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 120 Days
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

NCT02753946
View directory record Official record
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 28, 2026, 11:12 PM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Recruiting Phase 4 Interventional

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

NCT06954129
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Vancomycin, Piperacillin-tazobactam, Cefepime
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4
Biological · Genetic · Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 3 Interventional Results available

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

NCT01853982
View directory record Official record
Conditions
Ventilator-Associated Pneumonia (VAP)
Interventions
Ceftolozane/Tazobactam, Piperacillin/Tazobactam
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
11
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

NCT03269994
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases
Interventions
Cefoxitin, Piperacillin-tazobactam
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
29
States / cities
Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 28, 2026, 11:12 PM EDT
Recruiting No phase listed Observational

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

NCT06002607
View directory record Official record
Conditions
Necrotizing Soft Tissue Infection
Interventions
Antibiotic duration (short course), Antibiotic duration (extended course)
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Not yet recruiting Phase 2 Interventional

Cefotetan Therapy for Escherichia Coli Infections

NCT07318584
View directory record Official record
Conditions
E Coli Infection, ESBL Producing E.Coli
Interventions
Cefotetan, Carbapenems, Beta Lactam Antibiotics
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

SYN-004 Safety and Tolerability in Allo-HCT Subjects

NCT04692181
View directory record Official record
Conditions
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
Interventions
SYN-004, Ribaxamase or Placebo
Biological
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated No phase listed Observational

Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support

NCT03922451
View directory record Official record
Conditions
Drug Effect
Interventions
piperacillin-tazobactam, Cefazolin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 28, 2026, 11:12 PM EDT
Withdrawn Phase 2 Interventional

Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

NCT03862079
View directory record Official record
Conditions
Graft-versus-host Disease Prevention
Interventions
Best Practice, Fecal Microbiota Transplantation, Nystatin, Piperacillin-Tazobactam
Other · Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 4 Interventional

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

NCT03560232
View directory record Official record
Conditions
Open Fracture, Post-Op Wound Infection
Interventions
Ceftriaxone, Ampicillin/sulbactam, Piperacillin/tazobactam, Cefazolin + Gentamicin, Clindamycin + Gentamicin
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Warren, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

NCT03289351
View directory record Official record
Conditions
Perforated Appendicitis, Postoperative Infection
Interventions
Piperacillin, Tazobactam Drug Combination
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated No phase listed Observational

PK of Piperacillin/Tazobactam in Adults Undergoing ECMO

NCT03467854
View directory record Official record
Conditions
Acute Respiratory Failure With Hypoxia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 4 Interventional Results available

BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

NCT05102162
View directory record Official record
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 28, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698
View directory record Official record
Conditions
Gram-negative Bacteremia
Interventions
Intravenous Antibiotics, Oral Antibiotics
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis

NCT01697059
View directory record Official record
Conditions
Acute Appendicitis
Interventions
Piperacillin + Amoxicillin
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 28, 2026, 11:12 PM EDT